Strs Ohio raised its stake in shares of Zoetis Inc (NYSE:ZTS) by 29.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 579,431 shares of the company’s stock after buying an additional 132,718 shares during the quarter. Strs Ohio owned about 0.12% of Zoetis worth $58,331,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in shares of Zoetis during the first quarter valued at approximately $25,000. Berman Capital Advisors LLC purchased a new stake in Zoetis in the fourth quarter worth $26,000. Athena Capital Advisors LLC purchased a new stake in Zoetis in the fourth quarter worth $29,000. TCI Wealth Advisors Inc. grew its stake in Zoetis by 123.4% in the first quarter. TCI Wealth Advisors Inc. now owns 344 shares of the company’s stock worth $35,000 after purchasing an additional 190 shares during the period. Finally, Resources Investment Advisors Inc. purchased a new stake in Zoetis in the fourth quarter worth $31,000. 90.84% of the stock is owned by institutional investors.
NYSE ZTS traded up $0.62 during trading on Friday, hitting $102.29. 1,868,170 shares of the stock traded hands, compared to its average volume of 1,965,626. The stock has a market capitalization of $48.96 billion, a PE ratio of 32.68, a P/E/G ratio of 2.54 and a beta of 0.91. The company has a debt-to-equity ratio of 2.84, a current ratio of 4.05 and a quick ratio of 2.79. Zoetis Inc has a 12-month low of $78.90 and a 12-month high of $103.97.
The business also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Stockholders of record on Thursday, April 18th will be issued a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date is Wednesday, April 17th. Zoetis’s dividend payout ratio (DPR) is 21.09%.
A number of equities research analysts have recently commented on the company. Credit Suisse Group increased their target price on Zoetis from $102.00 to $112.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 2nd. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a research report on Monday, May 6th. BMO Capital Markets increased their price objective on Zoetis from $93.00 to $101.00 and gave the company a “market perform” rating in a research report on Monday, February 25th. Gabelli cut Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price objective on the stock. in a research report on Thursday, May 2nd. They noted that the move was a valuation call. Finally, UBS Group began coverage on Zoetis in a report on Wednesday, March 20th. They issued a “neutral” rating on the stock. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $103.15.
In related news, EVP Clinton A. Jr. Lewis sold 6,124 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $101.60, for a total transaction of $622,198.40. Following the completion of the sale, the executive vice president now directly owns 54,484 shares of the company’s stock, valued at approximately $5,535,574.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kristin C. Peck sold 11,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $86.79, for a total value of $998,085.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 410,333 shares of company stock valued at $38,674,547. Company insiders own 0.29% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: Forex
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.